BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

German Cancer Congress

The German Cancer Congress (DKK / Deutscher Krebskongress) is the largest and oldest congress covering cancer diagnostics and therapy in German-speaking countries. The 34th annual congress will take place from February 19th - 22nd, 2020, at the CityCube in Berlin. Thermal oncology experts, Dr. Sennewald Medizintechnik, will be exhibiting Pyrexar's hyperthermia system solutions in booth D1.5 in hall B.

If you are planning on attending, please make a note to attend Hyperthermia Interdisciplinary Working Group (IAH) session titled: Hyperthermia - Indications and Combinations, on Saturday, February 22nd, 2020.

CHAIRS: Daniel Zips MD, UMC Tubingen, Germany
Felix Krummradt, UMC Heidelberg, Germany
Peter Wust MD
UMC Charité Berlin
"Current state of technology and relevant studies."
Oliver Ott MD
UMC Erlangen
"Neoadjuvant radiochemotherapy with regional hyperthermia in rectal cancer (HyRec phase II study)"
Cihan Gani MD
UMC Tubingen
"Hyperthermia as part of organ-preserving therapy concepts for rectal cancer."
Rolf Isssels MD
UMC Munich Grosshadern
"Interim analysis of the HEAT phase III study on adjuvant therapy for pancreatic cancer."
Udo Gaipl PhD
UMC Erlangen
"Hyperthermia and immune response."

A complete schedule of events is available on the organization's website.

Pyrexar Medical is a proud sponsor of the Eleventh Biennial Conference of the IAHOM ( Indian Association of Hyperthermic Oncology and Medicine) held in Mumbai on 15th & 16th February 2020. The meeting is co-sponsored by the Society for Cancer Research and Communication and Nanavati Multispeciality Hospital.

Nanavati Hospital Vile Parle Mumbai

Topics at the conference include

    • Immunology relevant to Hyperthermia
    • Nanotechnology
    • Economics of setting up Hyperthermia Center in Emerging Economies
    • Hyperthermia from India HIPEC and HIFU
    • Innovations in Technology

 You may recognize several of the hyperthermia luminaries scheduled to speak which include, Dr. Zeljko Vujaskovic of the University of Maryland Medical Center, Dr. Jacoba van der Zee, Dr. Gerard van Rhoon, and Dr. Hans Creeze of Erasmus MC, The Netherlands, 

Indian association of hyperthermic oncology and medicinenanvati logo .Society of Cancer Research and Communication

A special thanks to Dr. Nagraj G. Hiulgol and Dr. Jugna Bhattacharya for their work in bringing hyperthermia awareness and education to India.

 Link to the conference brochure download.

 

Our friends at Thermosome continue to move their drug targeting platform forward. In a recent video, (shown below) they describe the development of their drug targeting system using focal heat as the release trigger.


BSD-2000 3D/MR makes an appearance at 01:03

Thermosome has developed a drug release system that targets the tumor with a 10 to 15 times higher local drug concentration over standard delivery. They do this by micro-encapsulating approved chemo drugs with a shell of thermosensitive liposomes (TSL). The TSL encapsulated drug is circulated via IV to the patient during the thermal therapy treatment, only releasing it when the surrounding environment reaches 42˚C, which is 5˚C higher than average body temperature.  

thermosome video

Deep Regional Hyperthermia plays an important role by creating the necessary 42˚C microenvironment around the tumor. Combining Thermosome with the BSD-2000 3D/MR provides stable temperatures in a defined focal region.  Additional patient benefit is derived from the positive thermal effects of increased blood flow and perfusion at the tumor site, the immune modulation generated by heating, and the increased concentration of chemotherapeutics.  The visual aspect of the MRI guidance (3D heat zone mapping) offers operator assurance that the tumor area is entirely at the target temperature when the drug is administered. 

Thermosome is actively looking for partners, learn more about at http://www.thermosome.com/

Hanoi High Tech and Digestive Center at the St. Paul Hospital in Vietnam launches its thermal oncology program with the assistance of Dr. Mark Hurwitz. In the photo above, Dr. Hurwitz is explaining the functions of the thermal mapping probe of the newly installed BSD-2000 3D deep regional hyperthermia system.

High Tech Digestive Center Hanoi Vietnam

Saint Paul General Hospital opened the Digestive Center in 2017, specializing in endoscopic surgery and the treatment of digestive disease including stomach and pelvic cancers. Built following European standards, it is the country’s leading endoscopic surgery facility.

Oncology team at High Tech Digestive Center, St. Paul Hospital, Vietnam

Dr. Hurwitz was invited to lecture on hyperthermia best practices and share his vast knowledge and experiences in the field of thermal oncology and its role in cancer treatment.

Thermal oncology training High Tech Digestive Center, St. Paul Hospital, Vietnam

Dr. Hurwitz is a globally known thermal oncologist and radiation oncologist. He is currently Vice-Chair for Quality, Safety & Performance Excellence, and Director of Thermal Oncology, Department of Radiation Oncology, at Jefferson Health, Sidney Kimmel Medical College.

Control center of a BSD-2000 3D system at High Tech Digestive Center, St. Paul Hospital, Vietnam

Often a featured lecturer at conferences throughout the U.S., Europe, and Asia, his hands-on clinical knowledge of both deep regional and superficial thermal therapy prepares new sites, like St. Paul, to become leaders in this cancer treatment technology.

A special thanks to Pyrexar Medical Vietnam distributor Thai Thinh Medical for sponsoring this event.